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Abstract 
Background: The homing capacity of human mesenchymal stem cells (hMSCs) to the injured sites enables systemic 
administration of hMSCs in clinical practice. In reality, only a small proportion of MSCs are detected in the target tis‑
sue, which is a major bottleneck for MSC‑based therapies. We still don’t know the mechanism how MSCs are chemo‑
attracted to certain target organ and engrafted through trans‑endothelial migration. In this study, we aimed to 
determine the mechanism how the circulating hMSCs home to the injured liver.
Methods and results: When we compare the cytokine array between normal and injured mouse liver at 1‑day thio‑
acetamide (TAA)‑treatment, we found that chemerin, CXCL2, and CXCL10 were higher in the injured liver than normal 
one. Among three, only chemerin was the chemoattractant of hMSCs in 2D‑ and 3D‑migration assay. Analysis of the 
signal transduction pathways in hMSCs showed that chemerin activated the phosphorylation of JNK1/2, ERK1/2 and 
p38, and finally upregulated CD44, ITGA4, and MMP‑2 that are involved in the transendothelial migration and extrava‑
sation of MSCs. Upstream transcription regulators of CD44, ITGA4, and MMP-2 after chemerin treatment were MZF1, 
GATA3, STAT3, and STAT5A. To develop chemerin as a chemoattractant tool, we cloned gene encoding the active 
chemerin under the CMV promoter (CMV‑aChemerin). We analyzed the migration of hMSCs in the 3D model for space 
of the Disse, which mimics transmigration of hMSCs in the liver. CMV‑aChemerin‑transfected hepatocytes were more 
effective to attract hMSC than control hepatocytes, leading to the enhanced transendothelial migration and homing 
of hMSCs to liver. The homing efficiency of the intravascularly‑delivered hMSCs to liver was evaluated after systemic 
introduction of the CMV‑aChemerin plasmid packed in liposome‑vitamin A conjugates which target liver. CMV‑
aChemerin plasmid targeting liver significantly enhanced homing efficiency of hMSCs to liver compared with control 
plasmid vector.
Conclusions: Chemerin is the newly found chemoattractant of hMSCs and may be a useful tool to manipulate the 
homing of the intravascularly‑administered hMSC to the specific target organ.
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Background
The homing capacity of mesenchymal stem cells (MSCs), 
which allows the cells to navigate to injured sites, ena-
bles systemic administration of MSCs in clinical prac-
tice. Homing includes transendothelial migration, which 
is guided by certain chemokines from the injured site. 
However, only a small proportion of MSCs is detected in 
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the target tissue, which has been a major bottleneck for 
MSC-based therapies [1].
The mechanisms underlying leukocyte and lymphocyte 
chemotactic responses and their attachment and pen-
etration through endothelial cells (ECs) are well-under-
stood; however, we don’t know well the mechanism how 
MSCs are chemoattracted and migrate through endothe-
lial barrier toward the final destination [2] or the injured 
liver in our study.
To improve the low efficacy of homing to the target 
sites via transendothelial migration, chemokines released 
from the injured tissue are reliable candidates of chem-
oattractants. Indeed, local inflammation induces hom-
ing of hMSCs as well as engraftment in mice [3]. Stromal 
cell derived factor (SDF)-1 from endothelial cells and its 
interaction with CXCR4, which is expressed in MSCs, is 
critical for this step [4, 5]. Therefore, studies have focused 
on raising homing efficiency of MSCs using CXCR4/
SDF-1α axis [4–6]. Studies have shown that the CXCR4/
SDF-1 axis is crucially involved in hematopoietic stem 
cell (HSC) homing in bone marrow niches [7]. How-
ever, the expression of CXCR4 on the surface of MSCs 
is controversial. Some groups have reported that CXCR4 
is important for MSC migration to the bone marrow, 
although its expression levels are low [8]. Other groups 
have reported that MSCs do not express CXCR4 [9]. 
Another study showed that MSCs express various other 
receptors and migrate toward a wide spectrum of signals 
[10–12]. Using these factors, as well as the CXCR4/SDF-1 
axis, various strategies have been applied to improve this 
step [1, 13]. However, homing of MSCs to target tissue 
after systemic administration is still inefficient.
Chemerin is a chemotactic protein that is mostly syn-
thesized and secreted by the liver, adipocytes, and lung 
[14]. It is secreted as an inactive precursor named pro-
chemerin and is activated by different proteases depend-
ing on the injured site [14]. The last 6 to 7 amino acids 
at the C terminus of pro-chemerin are cleaved to obtain 
biologically active chemerin [15, 16]. Active chemerin 
mainly interacts with the G protein-coupled receptor 
ChenmR23, which has been detected in leukocyte pop-
ulations such as macrophages, natural killer cells, and 
dendritic cells [17]. The interaction of chemerin with 
ChemR23 leads to migration of the cells to injured sites 
[18].
In the previous study, we tried to test whether hMSCs 
can alleviate liver fibrosis after injury and administered 
hMSCs via the systemic route in mouse model of liver 
injury using thioacetamide (TAA) [19]. We observed 
homing of several hMSCs to the injured liver, leading to 
reduction of liver fibrosis. In the current study, we aimed 
to identify the hMSC chemoattractant that is secreted 
from the injured tissue to improve the homing efficiency 
of hMSCs to the injured liver and then maximize the 
therapeutic effect of hMSCs. We analyzed the expression 
profile of chemokines from the injured liver and discov-
ered chemerin as a practical tool to enhance the homing 
of hMSCs after systemic administration into target tissue.
Results
Screening chemoattractant of hE‑MSC toward the injured 
liver
Previously, we have constructed a mouse liver fibrosis 
model using a well-established TAA-induced liver fibro-
sis protocol [19, 20]. hE-MSCs were injected according to 
the time table shown in Fig. 1 to confirm the therapeutic 
effect of hE-MSCs. To visualize the cells, we labeled hE-
MSCs with DiI and systemically administered them one 
day after TAA treatment. We observed the DiI-labeled 
hE-MSCs that infiltrated to liver at day 14 after systemic 
administration (Fig.  1A). To screen potential chemoat-
tractants in liver, the cytokine array was used on normal 
and TAA-treated liver tissue. Short exposure of the film 
showed that the chemerin levels in TAA-treated liver 
were higher than that in the normal liver. Longer expo-
sure showed increase in the expression of CXCL2 and 
CXCL10 also (Fig. 1B).
To validate three candidates, a 3D transendothe-
lial migration system was constructed using a DiO-
labeled HUVEC layer on top of collagen which was 
supplemented with chemokines (CXCL2, CXCL10, and 
chemerin). We applied DiI-labeled hE-MSCs on HUVEC 
layer and observed for 72  h that hE-MSCs migrated 
through HUVEC toward chemerin-supplemented colla-
gen matrix but not toward CXCL2- or CXCL10-supple-
mented collagen (Fig. 1C).
To determine whether chemerin can be used on other 
cell types, we checked the applicability of chemerin in 
hBM-MSCs. Chemerin attracted hBM-MSCs also in the 
2D migration assay, which was blocked by the neutraliz-
ing antibody against chemerin (Fig. 1D).
Chemerin induced migration‑related gene expression 
in hBM‑MSCs
To determine the action mechanism of chemerin in 
hBM-MSCs, first we checked the phosphorylation status 
of JNK1/2, ERK1/2, and p38, which have been reported 
to be activated when chemerin interacts with ChemR23 
[21]. Chemerin significantly increased the phospho-
rylation status of these proteins (Fig.  2A). Next, we 
assessed the expression of transmigration-related genes 
of MSCs, including CD44, ITGA4, and MMP2, and 
observed increase in mRNA and protein levels of these 
genes (Fig. 2B, C). To understand the regulatory mecha-
nism, the common transcription factors that bind to the 
promoter regions of CD44, ITGA4, and MMP2 were 
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screened using the Gene Promoter Miner to detect com-
mon transcription factors under the key word ‘transmi-
gration’. And then the screened factors were filtered again 
by searching for research papers on transmigration in 
NCBI (National Center for Biotechnology Information) 
(Fig.  2D) [22–26]. The common transcription factors 
that bind to the promoter regions of CD44, ITGA4, and 
MMP2 and are involved in transmigration were GATA3, 
MZF1, STAT3, and STAT5A (Fig.  2D). The mRNA of 
Fig. 1 Screening of chemoattractant candidates for hMSCs. A Liver fibrosis model was generated by injecting TAA (0.2 mg/mL) every 2 days to 
the mouse. DiI‑labeled hE‑MSCs were systemically administered after the first TAA injection. DiI‑labeled hE‑MSCs were found in mouse liver treated 
with TAA. DiI hE‑MSCs are red and the nuclei are blue. B Mouse chemokine array blots of normal and the injured liver at 1‑day after TAA‑treatment. 
The upper blot was exposed for 5 min and the bottom blot was exposed for 10 min. Chemokines are shown as duplicate dots. Reference dots are 
shown at the periphery; top right and left as well as bottom left. White squares indicate chemokines that were significantly increased in the injured 
mouse liver with TAA (0.2 mg/mL). The data shown were reproducible results from two independent experiments. Blots were quantified by Image 
J software. (C) 3D transmigration assay. Upper panel shows the scheme. The 3D transmigration system constructed using DiO‑labeled HUVECs 
(green) as the endothelial layer on the surface of collagen gel below containing a given chemokine such as CXCL2, CXCL10, or chemerin (all at 
50 pM). DiI‑labeled hE‑MSCs (red) were seeded on HUVECs and their migration into collagen gel was observed for 72 h by performing Z‑stacking 
in a confocal microscope. Migration distances of hE‑MSCs are indicated on a scale of 40 µm. The data shown are reproducible results from two 
independent experiments. D 2D random migration assay of hBM‑MSC in response to chemerin or ChemR23 blocker (ChemR23 neutralizing 
antibody). Quantification of cell migration at 12 and 24 h was represented as the percentage of cell coverage in the initial cell‑free zone. The white 
bar represents control hBM‑MSCs, the gray bar indicates hBM‑MSCs exposed to chemerin in media, and the black bar indicates hBM‑MSCs that 
were treated with the ChemR23 neutralizing antibody in addition to chemerin
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these four factors increased by treatment with chemerin 
(Fig. 2E).
Construction of chemerin vector to attract hMSC in vitro 
model
To use chemerin as a chemoattractant of hMSC, we 
designed a CMV-mouse chemerin vector (CMV-
mChemerin) (Fig.  3A). Chemerin is activated after the 
cleavage of the last 6 or 7 amino acids at the C terminus 
depending on the enzyme. Hence, we designed this vec-
tor to encode an active form of chemerin that does not 
contain the last six amino acids, and thus can directly 
bind to ChemR23 without requiring any processing. 
Expression of this vector was detected and evaluated in 
293 T cells. Active chemerin (~ 16 kDa) was detected in 
the cell culture supernatant and cell lysate (Additional 
file 1: Figure S1A). Interestingly, two bands were detected 
in the cell culture supernatant. The size of the upper band 
was 19  kDa reflecting inclusion of the signal peptide at 
the N-terminus, while the lower band was 16 kDa lack-
ing the region. Using the culture supernatant of 293 T 
cells transfected with pCMV-aChemerin, we performed 
2D migration of hBM-MSCs to confirm the function of 
the active chemerin construct. The random migration 
of hBM-MSCs was activated in the culture supernatant 
from cells transfected with the pCMV-aChemerin vector 
more than supernatant from un-transfected control cells 
(Additional file 1: Figure S1B).
Next, to validate the transendothelial migration, we 
developed a 3D transendothelial migration assay model, 
which mimics the transendothelial migration of MSCs in 
the space of Disse of the injured liver (Fig. 3B). We con-
structed this environment by (1) embedding in collagen 
the pCMV-aChemerin vector-transfected Hepa-1c1c7 
cells (mouse hepatocyte) which represented the injured 
liver, (2) adding DiO-labeled MS-1 cells (mouse pancre-
atic islet endothelial cell) on top of this cell-collagen mix 
as an endothelial layer of the space of Disse, and finally 
(3) inoculating DiI-stained hBM-MSCs on the top of this 
structure. Active chemerin expression in Hepa-1c1c7 
cells was confirmed using western blotting (Fig. 3C). We 
observed that hBM-MSCs penetrated the MS-1 layer and 
migrated effectively toward Hepa-1c1c7 cells transfected 
with CMV-aChemerin (Fig. 3D).
Fig. 1 continued

































































































Fig. 2 Chemerin induced phosphorylation of JNK1/2, ERK1/2, and p38 and increased the expression of migration‑related genes in hBM‑MSCs. 
A Western blot of phosphorylated JNK1/2, p38, and ERK1/2 in hBM‑MSCs after chemerin treatment. Protein expression was quantified using the 
Image J software. Expression was normalized to that of GAPDH (N > 3). B RT‑qPCR of CD44, ITGA4, and MMP‑2 after chemerin treatment. mRNA 
levels were observed 24 h after the chemerin treatment of BM‑MSCs. C Western blot analysis of CD44, ITGA4, and MMP‑2 of hBM‑MSCs after 
chemerin treatment. Protein expression was quantified using Image J and normalized to GAPDH level. D Venn diagram of common transcription 
factors, CD44, ITGA4, and MMP2. Transcription of each gene was found using GP miner and 26 genes were found to encode common transcription 
factors. Among these transcription factors, five were involved in transmigration. GP miner (http:// gpmin er. mbc. nctu. edu. tw/). E RT‑qPCR of 
transcription factors in naïve and chemerin‑treated hBM‑MSCs. The data shown were reproducible results from three independent experiments
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The homing of systemically‑administered hMSCs into liver 
by chemerin vector in liposome‑vitamin A conjugate 
in vivo
To validate the functionality of the chemerin vector to 
attract hMSCs in  vivo, we intraperitoneally injected the 
vector into normal mouse. The vector was contained in 
liposome-vitaminA conjugate to target liver [19, 27]. Two 
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systemically administered via intra-cardiac injection. The 
livers were harvested 3 days after systemic introduction 
of DiI-hBM-MSCs to count the homing of these DiI-pos-
itive cells into liver. Homing of the systemically-adminis-
tered hBM-MSCs to liver was significantly greater after 
introduction of pCMV-aChemerin in liposome-vitamin 
A conjugate than after pCMV-GFP control vector (Fig. 4 
and Additional file 1: Figure S2).
Discussion
Limitation in clinical application of systemic 
transplantation of MSCs
The important issue in the clinical application of hMSCs 
that are most frequently used in real world practice is to 
achieve the best homing and engraftment efficacy to tar-
get tissue. Direct transplantation of hMSCs in the target 
region is the simplest method that cannot be applicable 
for most of the target organs. Instead, vascular delivery of 
hMSCs would be a plausible alternative one that has limi-
tation such as poor homing or engraftment to the target 
organ. Transendothelial migration of MSCs that were 
introduced in the circulation may be the determinant of 
the homing efficacy of hMSCs to specific target tissue.
Discovery of chemoattractant of hMSCs
In order to find out chemoattractant of the circulating 
hMSCs, we paid attention to the higher rate of hom-
ing of hMSCs to the injured liver than normal one after 
intravascular administration. We compared cytokine 
array between normal and the injured liver, and found 
that chemerin, CXCL2, and CXCL10 were the prominent 
three proteins that were higher in the injured liver than 
normal one. Among three factors only chemerin was 
the effective chemoattractant of hMSCs in the in  vitro 
transendothelial migration assay.
In terms of CXCL10, it selectively recruits CXCR3-
expressing T cells (CD4+, CD8+ and NK cells during 
inflammation [27]. When liver is inflamed, hepatocyte 
secretes CXCL10, thus recruiting CXCR3-expressing 
cells such as T cells, Kupffer cells, and hepatic stellate 
cells [28]. In terms of CXCL2, it is also produced by 
macrophages, monocytes, epithelial cells and hepato-
cytes during inflammation in liver. CXCL2 secreted 
form Kupffer cells attracts and activates neutrophils, 
leading to release of inflammatory mediators [29]. 
In terms of chemerin, it upregulates adhesion mol-
ecules on endothelial cells which enhances monocyte 
adhesion and development of atherosclerosis. Also, 
Fig. 3 Construction of active chemerin vector. A Scheme showing the active chemerin vector. Twenty amino acids at N‑terminus represent 
the signaling peptide that assists secretion of chemerin from hMSCs. The last six amino acids at C‑terminus are enzymatically cleaved away 
leaving active chemerin. B Scheme for 3D mimesis of the space of Disse. The upper panel shows the possibility of transendothelial migration 
of hBM‑MSCs in the space of Disse. To observe the possibility of ex vivo migration, a similar environment was constructed using Hepa‑1c1c7 
(hepatocytes), MS‑1 (endothelial cells), and hBM‑MSCs. C Evaluation of the vector in Hepa‑1c1c7. Levels of the vector‑encoded protein in the 
lysate and media of Hepa‑1c1c7 cells transfected with the vector were detected using western blotting. The cell lysate shows different‑sized 
chemerin and the supernatant shows inactive and active chemerin. Recombinant mouse chemerin (rmChemerin) was loaded as the positive 
control. D Transendothelial migration of hBM‑MSCs. Penetration of hBM‑MSCs through MS‑1 cells into collagen matrix containing Hepa‑1c1c7 cells 
transfected with active chemerin vector. MS‑1 was labeled with DiO (green) and hBM‑MSC was labeled with DiI (red). Migration in the vertical side 
of the collagen matrix was observed using the Z stack of the confocal microscope. The migration distances of hBM‑MSCs were indicated in the scale 
of 50 µM. The data shown were reproducible results from two independent experiments
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Fig. 3 continued
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chemerin is involved in inflammation by activating 
p38 MAPK pathway in renal injury and inhibits CCL2 
secretion in allergic asthma, leading to recruitment of 
inflammatory dendritic cells. Thus, when inflamma-
tion occurs, chemerin acts as an anti-inflammatory or 
pro-inflammatory mediator [30]. In the current study, 
Fig. 3 continued
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chemerin is secreted from the damaged liver, acts as a 
chemoattractant of hMSC, leading to their homing to 
liver.
Transmigration of MSCs from the blood to a specific 
organ involves several steps. The first step is that the cir-
culating MSC tether to endothelial cells via interaction 
between CD44 on MSCs and selectin on endothelial cells 
[28]. Next, VLA4 (heterodimer of ITGA4 and ITGB1) of 
MSCs interacts with VCAM1 of endothelial cells, result-
ing in the rolling and arrest of MSCs [28, 29]. Finally, 
MMP-2 secretion is required for the invasion of MSCs 
through the basement membrane of the endothelium and 
cleavage of the extracellular matrix for MSCs to arrive at 
the desired target [28, 29]. In this study, we observed that 
CD44, ITGA4, and MMP-2 in MSCs were induced by 
chemerin. We deciphered the upstream regulator mecha-
nisms, such as, phosphorylation of JNK1/2, ERK1/2 and 
p38, and then induction of transcription factors MZF1, 
GATA3, STAT3, and STAT5A.
Active chemerin as a practical tool to guide hMSCs 
into target organ
Our results indicated that chemerin stimulated the 
expression of transmigration-related genes via these 
transcription factors  (Fig.  5). We observed up-regula-
tion of MMP-2 by MSCs in response to chemerin, as 
well as CD44 and ITGA4. Previous studies have shown 
that MMP-2 is required for transendothelial migration 
of MSCs [30]. Therefore, for practical application of 
chemerin, we constructed an active chemerin which does 
Fig. 4 Applicability of the active chemerin vector in vivo. A Confocal microscopy images of DiI‑labeled hBM‑MSCs that homed to liver after 
systemic administration in mouse. Homing to liver was enhanced by pretreatment of pCMV‑aChemerin vector in liposome‑vitamin A conjugate. 
Red indicates DiI‑labeled hBM‑MSCs and blue indicates the nuclei. Confocal images were captured as a 6.25  mm2 square at random and the 
DiI‑positive cells were counted manually (N > 20). B Results represent the mean ± standard deviation of two independent experiments
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not require processing for activation. The signal peptide 
(20 amino acids) was retained for extracellular secretion. 
Proteins of various sizes were observed in the cell lysate, 
including chemerin with the signal peptide (~ 19  kDa) 
as well as the active chemerin of the predicted size 
(~ 16  kDa) in the culture supernatant. Secreted active 
chemerin attracted hMSCs through the endothelial bar-
rier into target chamber ex  vivo or into liver in  vivo. 
The vector was delivered via the non-invasive route and 
targeted to the liver via liposome-vitamin A conjugate. 
However, further studies are required to develop the vec-




Human MSCs derived from embryonic stem cells (hE-
MSCs) were obtained using a previously reported proto-
col [31]. hE-MSCs were cultured in EGM-2MV medium 
(Lonza, Switzerland, CC-3202). Bone marrow MSCs 
(hBM-MSCs) were purchased (Lonza; PT-2501) and cul-
tured in mesenchymal stem cell growth medium 2 (Pro-
mocell, Germany; C-28009). Hepa-1c1c7 cells (ATCC, 
United Kingdom; CRL-2026) were cultured in 10% fetal 
bovine serum (FBS)-supplemented minimal essen-
tial medium (MEM) (Thermo Fisher Scientific, USA; 
11095080). HUVECs (Lonza; CC-3202) were cultured in 
EGM 2MV (Lonza; CC-3202). MS-1 cells (ATCC; CRL-
2279) were cultured in 5% FBS-supplemented Dulbecco’s 
modified Eagle’s medium (DMEM) (Thermo Fisher Sci-
entific; 11995065). FBS was from Gibco (Thermo Fisher 
Scientific; 16000). All cells were incubated at 37 °C in the 
presence of 5%  CO2.
Chemokine array
The Proteome Profiler Mouse Chemokine Array kit 
(R&D system, United State, ARY020) was used according 
to the manufacturer’s protocol.
Western blotting
Cells were harvested in radioimmunoprecipitation assay 
(RIPA) buffer (Thermo Fisher Scientific; 89900) and 
were agitated on ice for 15  min, after which the lysates 
were centrifuged at 13,000  rpm, 4 ℃, for 10  min. Then, 
the supernatants were collected and quantified using 
the bicinchoninic acid (BCA) protein assay kit (Thermo 
Fisher Scientific; 23225). The proteins were loaded on 
10% Tris–glycine sodium dodecyl sulfate (SDS)-poly-
acrylamide gel and transferred to membranes. The mem-
branes were blocked in 5% normal horse serum (NHS) 
(Sigma-Aldrich, United State, H1270-500ML) for 1  h, 
followed by addition of primary antibodies and overnight 
incubation. Following are the primary antibodies used: 
anti-mChemerin (1:1000; R&D System, USA; AF2325), 
anti-phopspho-JNK (1:1000, Cell Signaling Technology, 
USA; 4668), anti-JNK (1:1000, Cell Signaling Technology; 
9252), anti-phospho-p38 (1:1000, Cell Signaling Tech-
nology; 4511), anti-p38 (1:1000, Cell Signaling Technol-
ogy; 8690), anti-phospho-ERK1/2 (1:1000, Cell Signaling 
Technology; 4370), and anti-ERK1/2 (1:1000, Cell Signal-
ing Technology; 4695). An anti-GAPDH (1:5000, Thermo 
Fisher Scientific; MA5-15738) antibody was used as 
an internal housekeeping control. The immunoblotted 
membranes were incubated with horse radish peroxidase 
(HRP)-conjugated secondary antibodies (1:2000, Jackson 
ImmunoResearch Laboratories).
Quantitative polymerase chain reaction (qPCR)
RNA was isolated from cells using TRIzol (Invitrogen, 
United State, 15596026) per the manufacturer’s proto-
col and RNA concentration was quantified using a Nan-
oDrop (Thermo Fisher Scientific; ND-ONE-W4). One 
microgram RNA was transcribed into cDNA using the 
RT master premix (oligo d(T) kit (Elpis Biotech, Korea; 
EBT-1512). All reactions were made using FastStart Uni-
versal SYBR Green master (Rox) mix (Merck Millipore, 
Germany; 4913850001). RT-qPCR was performed for 40 
cycles of 95 ℃ for 15 s, 60 ℃ for 15 s, and 72 ℃ for 30 s 
using ABI Prism 7500 (Applied Biosystems, USA).
The sequences of the primers used are as follows:
hCD44 Forward: 5′CGA AGA AGG TGT GGG CAG 
AAG 3′
hCD44 Reverse: 5′CGA CTC CTT GTT CAC CAA ATGC 
3′
hITGA4 Forward: 5′TAG CCC TAA TGG AGA ACC 
TTGTG 3′
hITGA4 Reverse: 5′TCT ATG CCC ACA AGT CAC 
GATG 3′
hMMP2 Forward: 5′GCC AAG TGG TCC GTG TGA AG 
3′
hMMP2 Reverse: 5′CAA AGT TGT AGG TGG TGG 
AGCA 3′
hGATA2 Forward: 5′ GCC ACA GCC ACC CCT CTC 3′
hGATA2 Reverse: 5′ GGT TGT CGT CAG TCT TCG 
CTT 3′
hGATA3 Forward: 5′ CAC CCC ATC ACC ACC TAC CC 
3′
hGATA3 Reverse: 5′ CCT GCC TGT GCT GGA CCG 3′
MZF1 Forward: 5′ CTT CTC CCC AGG GTT CGC 3′
MZF1 Reverse: 5′ GCG GGA GGG TGA TTG GAT 3′
hSTAT3 Forward: 5′CTA GAG ACC CAC TCC TTG 
CCAG 3′
hSTAT3 Reverse: 5′TTT ACA TTC TTG GGA TTG 
TTGGT 3′
hSTAT5A Forward: 5′GTC CTG AAG ACC CAG ACC 
AAGT 3′
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hSTAT5A Reverse: 5′CTC GTT GCG GGT GTT CTC AT 
3′
2D migration assay
hBM-MSCs (1.0 ×  104) were plated in each of the ibidi 
culture-insert 2 wells (ibidi, USA; 81,176) and incu-
bated overnight in desired media at 37  °C in the pres-
ence of 5%  CO2. The next day, the insert 2 well was 
removed and the medium was replaced with 0.5% FBS. 
Next, 50  pM of mChemerin (R & D Systems; 2325-
CM-025), mCXCL2 (PeproTech, USA; 205-15), and 
mCXCL10 (PeproTech; 250-16) were added to the cells. 
The cells were observed and images were captured after 
every 6 h. The images were quantified using Image J.
3D transmigration
Three hundred microliters of the collagen mixture 
from 3D collagen cell culture system (Merck Milli-
pore, USA; ECM 675) were plated in eight wells (ibidi, 
United State 80826) and solidified in a 5%  CO2 incuba-
tor for 1 h. After solidification of collagen, 5 ×  104 DiO 
(Thermo Fisher Scientific; V22886)-labeled HUVECs 
were plated. Once the HUVECs had attached, 5 ×  104 
DiI (Thermo Fisher Scientific; C7001)-labeled hE-MSCs 
were plated. These cells were incubated for 3 days and 
observed using a confocal microscope (Leica Microsys-
tem, South Korea; Leica STED CW).
3D mimesis model for space of Disse
Hepa-1c1c7 cells transfected with pCMV-Flag-tagged 
mouse chemerin were trypsinized and mixed with col-
lagen from the 3D collagen cell culture system (Merk 
Millipore; ECM 675). Three hundred microliters of the 
collagen-cell mixture were plated in eight wells (ibidi, 
United State 80826) and the collagen was solidified in 
5%  CO2 incubator for 1 h, following which, 5 ×  104 DiO 
(Thermo Fisher Scientific; V22886)-labeled MS-1 cells 
were plated. Once the MS-1 cells had attached, 5 ×  104 
DiI (Thermo Fisher Scientific, United State, C7001)-
labeled hBM-MSCs were plated. These cells were incu-
bated for 2  days and then observed using a confocal 
microscope (Leica Microsystem).
Vector construction
Prochemerin has a signaling peptide at the N-terminus 
and is enzymatically cleaved at the C-terminal. For 
generating active chemerin, we constructed a pCMV-
aChemerin vector that included the signal peptide at 
the N-terminus and lacked the last six amino acids at 
the C-terminus. pCMV-mGFP (Origene) was used as 
the backbone vector.
Mouse liver fibrosis model and cell transplantation
All animal study protocols were approved by the Insti-
tutional Animal Care and Use Committee (IACUC) of 
the Seoul National University Hospital, Korea. The IRB 
number is H-1410-093-619. BALB/c-nude mice (male, 
12–13 weeks old, 20–25 g) (Orient, South Korea) were 
used for all animal experiments. Mice were admin-
istered 200  mg/kg TAA (Sigma-Aldrich; 163678) via 
intraperitoneal injection thrice per week for 14  days. 
Animals in the negative control group were injected 
with 0.9% saline. Cells were transplanted via intra-
cardiac injection 1  day after the first TAA injection 
(Fig.  1A). Prior to cell injection, the hE-MSCs were 
stained with 1  mg/mL CellTracker CM-DiI (Thermo 
Fisher Scientific; C7000) and incubated at 37  ℃ for 
24 h. Fourteen days’ post-cell transplantation, liver tis-
sue was harvested for histology.
CMV‑aChemerin vector injection
The CMV-aChemerin vector and emerald GFP vector 
(OriGene) were incubated with the lipotrust-vitamin 
A complex. Lipotrust (CSR-LEO-10-EX, Cosmobio): 
retinol (Sigma; R7632) were mixed in ratio of 240:120 
(nmol). Then, 18.5  µg vector was added to 100  nmol of 
the retinol:lipotrust complex and incubated for 20 min at 
room temperature. After 20 min, the complex was filtered 
using a PES column (Sartorius, Germany; VS0221) at 
1500×g for 5 min at 25 ℃. Then, this complex was eluted 
with phosphate buffered saline (PBS) to a total volume of 
70  µL and was intraperitoneally injected into BALB/c-
nude mouse that were anesthetized with tribromoetha-
nol. Two days after vector injection, hBM-MSCs were 
injected via cardiac injection. For hBM-MSC injection, 
1.0 ×  106 hBM-MSCs were collected and incubated with 
CM-DiI dye (1 mg/mL) (Thermo Fisher Scientific; C7000) 
for 5 min at 37 °C and then incubated at 4 ℃ for 10 min. 
After 15 min, the cells were centrifuged at 1200 rpm for 
5 min and washed twice with PBS. Then, the cells were 
suspended in PBS and 1.0 ×  105 were injected into each 
mouse. Two days after hBM-MSC injection (5 days after 
vector injection), mouse liver were harvested and fixed in 
4% paraformaldehyde for 3 and 7 days or frozen in liquid 
nitrogen for protein analysis.
Quantification of DiI‑positive cells in vivo
Tissue harvested from mouse were fixed in 4% para-
formaldehyde for 3 days and exchanged in 15% and 30% 
sucrose gradually until the tissue sank. Then, the tis-
sue block was embedded in optimal cutting tempera-
ture compound (OCT) (Sakura Finetek, United State, 
HSK-4583) below − 20  ℃. Next, these tissues were 
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cryosectioned at 7  µM. The nuclei were stained with 
4′,6-diamidino-2-phenylindole (DAPI) for 15  min in 
PBS and washed thrice with PBS. DiI-hBM-MSCs were 
observed in each group using a 555 nm laser of a Leica 
confocal microscope.
Statistical analysis
Experiments and groups were performed in triplicates, 
and all data were calculated as mean ± SD. Group com-
parisons were performed using the T-test, and the 
number of asterisks on the top of each graph indicated 
Fig. 5 Schemes explaining the mechanism how chemerin chemo‑attracts the circulating MSCs to the injured liver. Chemerin secreted from the 
injured liver interacts with ChemR23 on surface of MSCs, leading to activation of adhesion molecules that mediate steps of trans‑endothelial 
migration of the circulating MSCs to the injured liver
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statistical significance. *,**, and *** indicated that the 
p-value range was 0.01 to 0.05, 0.001 to 0.01, and 0.0001 
to 0.001, respectively.
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Additional file 1: Fig. S1. (A) Evaluation of the vector in 293 T cells. 
Western blotting of cell lysate and supernatant of pCMV‑mChemerin‑
transfected 293 T cells. (B) Evaluation of the vector by 2D migration assay. 
Under the supernatant of pCMV‑aChemerin‑transfected 293 T cells, 2D 
random migration of hBM‑MSCs were analyzed at 6 and 12 h. Fig. S2. 
Evaluation of human cells engrafting in mouse liver tissue. Genomic DNA 
from mouse liver tissue was extracted and analyzed by PCR for presence 
of human genome using equal amount. Genomic DNA of 293 T cells was 
used as a positive control. Human genomic DNA‑specific primers; forward: 
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